CD8A and acute myeloid leukemia: While few studies have analyzed the immunological markers in patients receiving PD-1 inhibitors, some have demonstrated higher CD3+ and CD8+ T cells in pre-therapy PB and BMA to be a marker of response to immunotherapy in adult AML patients [7].